386750-22-7 Desvenlafaxine succinate monohydrate AKSci V1481

Loading Please Wait...

V1481
Desvenlafaxine succinate monohydrate, 98% (HPLC), powder

Structure N/A

IDENTITY
CAS Number:	386750-22-7
MDL Number:	MFCD11877765
MF:	C20H33NO7
MW:	399.48

SPECIFICATIONS & PROPERTIES
Purity:	98% (HPLC), powder
Spectra:	FT-IR, LCMS, HPLC
Physical Form:	White powder
Melting Point:	127-135°C
Long-Term Storage:	Store long-term at -20°C

BIOLOGICAL INFO
Solubility:	DMSO: 20mg/mL
Application(s):	Serotonin-norepinephrine reuptake inhibitor (SNRI class)

REVIEW
Desvenlafaxine, the major active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor. The clinical effect of desvenlafaxine is thought to occur via potentiation of serotonin and norepinephrine in the central nervous system. Unlike venlafaxine, desvenlafaxine is thought to have a differential serotonergic and noradrenergic activity profile.

REFERENCES

[1]	Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of Infant Dose Through Milk in a Lactating Woman Taking Amisulpride and Desvenlafaxine for Treatment-Resistant Depression. Ther Drug Monit. 2010 Oct 5.
[2]	Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97.
[3]	Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96.
[4]	Liebowitz MR, Tourian KA: Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder:A Systematic Review of Clinical Trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845.